香港電台:消息指最快本週內公佈擴大互聯互通相關安排
香港電台報道,行政長官林鄭月娥公佈的《施政報告》提到,在港上市,未有盈利生物科技公司,和內地科創板股票,將納入「互聯互通」選股範圍。
政府消息人士指,相關安排最快在本週內公佈,目前共有24隻未有盈利生物科技公司於本港上市,在符合現有的特定條件下,例如被納入恆生綜合大型、中型股指數;或符合市值等要求,就可被納入互聯互通。
港交所主席史美倫表示,特區政府積極支持滬深港互聯互通機制進一步擴容,有助於確保香港資本市場活力,並不斷提升競爭力和吸引力。
第二上市股份未納入港股通
此前,市傳第二上市股份今次會被一同納入,但最終落空。有分析人士稱,第二上市股份遲早仍會納入範圍,只是時間問題。
受消息影響,二次上市股票午後出現跳水行情,新東方-S一度跌超6%,百勝中國-S跌超2%,京東集團-SW、阿里巴巴-SW一度跌超2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.